HomeBUSINESS
BUSINESS

Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
(Apr.19.2018)

Chugai Pharmaceutical’s anti-PD-L1 antibody Tecentriq (atezolizumab) was launched on April 18 to mark the debut of the PD-L1 class in Japan’s lung cancer space as a raft of new drugs joined the NHI price list on the same day, with AstraZeneca’s first-in-class PARP inhibitor Lynparza (olaparib) among them ...
(LOG IN FOR FULL STORY)